📊 EXOZ Key Takeaways
Is Exozymes Inc.. (EXOZ) a Good Investment?
Exozymes is a pre-commercial biotech company burning $1.5M annually with only $70.1K in revenue and $1.4M cash, providing approximately 11 months of operational runway before requiring capital raises. The company exhibits severe cash burn relative to assets and no visible path to profitability, making imminent shareholder dilution from equity financing highly likely.
Exozymes shows extremely weak fundamental operating performance, with negligible revenue relative to a multi-million-dollar loss base and deeply negative operating, net, and free cash flow margins. While the balance sheet is currently supported by solid liquidity, low liabilities, and no meaningful debt, the business does not yet demonstrate scalable revenue generation or a credible path to self-funded profitability.
Exozymes Inc.. Key Strengths (EXOZ)
- Zero debt burden eliminates leverage risk and preserves financial flexibility
- Liquid asset position of $1.4M provides near-term operational cushion
- Active insider participation with 6 Form 4 filings in 90 days indicates management engagement
- Strong near-term liquidity with $5.10M in cash and a 4.53x current ratio
- Low balance-sheet leverage with essentially no long-term debt
- Positive equity base of $5.37M provides some financial cushion
EXOZ Stock Risks: Exozymes Inc.. Investment Risks
- Critical cash runway of ~11 months at current $1.5M annual operating burn rate creates imminent capital requirement
- Pre-commercial status with only $70.1K revenue shows no meaningful market traction or commercialization progress
- Inevitable equity capital raises will cause substantial shareholder dilution; negative ROE (-155.1%) and ROA (-59.0%) destroy shareholder value
- Revenue remains extremely small at $70.07K versus $6.50M net loss, indicating a highly unproven commercial model
- Cash burn is severe, with negative operating cash flow of $4.53M and free cash flow of $4.62M
- Profitability metrics are deeply negative, including -10020.1% operating margin and -121.0% ROE
Key Metrics to Watch
- Quarterly cash burn rate and remaining months of runway
- Revenue growth, product commercialization traction, and path to profitability
- Capital raising activity, dilution from future equity issuance, and clinical/regulatory trial progress
- Quarterly revenue growth and commercialization traction
- Operating cash burn relative to cash balance
Exozymes Inc.. (EXOZ) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Exozymes Inc.. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
EXOZ Profit Margin, ROE & Profitability Analysis
EXOZ vs Healthcare Sector: How Exozymes Inc.. Compares
How Exozymes Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Exozymes Inc.. Stock Overvalued? EXOZ Valuation Analysis 2026
Based on fundamental analysis, Exozymes Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Exozymes Inc.. Balance Sheet: EXOZ Debt, Cash & Liquidity
EXOZ Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Exozymes Inc..'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.89 indicates the company is currently unprofitable.
EXOZ Revenue Growth, EPS Growth & YoY Performance
EXOZ Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2024 | $70.8K | -$178.1K | $-0.08 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Exozymes Inc.. Dividends, Buybacks & Capital Allocation
EXOZ SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Exozymes Inc.. (CIK: 0002010788)
📋 Recent SEC Filings
❓ Frequently Asked Questions about EXOZ
What is the AI rating for EXOZ?
Exozymes Inc.. (EXOZ) has a Combined AI Grade of D from Claude (D) and ChatGPT (D) with 88% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are EXOZ's key strengths?
Claude: Zero debt burden eliminates leverage risk and preserves financial flexibility. Liquid asset position of $1.4M provides near-term operational cushion. ChatGPT: Strong near-term liquidity with $5.10M in cash and a 4.53x current ratio. Low balance-sheet leverage with essentially no long-term debt.
What are the risks of investing in EXOZ?
Claude: Critical cash runway of ~11 months at current $1.5M annual operating burn rate creates imminent capital requirement. Pre-commercial status with only $70.1K revenue shows no meaningful market traction or commercialization progress. ChatGPT: Revenue remains extremely small at $70.07K versus $6.50M net loss, indicating a highly unproven commercial model. Cash burn is severe, with negative operating cash flow of $4.53M and free cash flow of $4.62M.
What is EXOZ's revenue and growth?
Exozymes Inc.. reported revenue of $70.1K.
Does EXOZ pay dividends?
Exozymes Inc.. does not currently pay dividends.
Where can I find EXOZ SEC filings?
Official SEC filings for Exozymes Inc.. (CIK: 0002010788) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is EXOZ's EPS?
Exozymes Inc.. has a diluted EPS of $-0.28.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is EXOZ's fundamental grade?
Based on our AI fundamental analysis in June 2026, Exozymes Inc.. has a D grade with 88% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is EXOZ stock overvalued or undervalued?
Valuation metrics for EXOZ: ROE of -155.1% (sector avg: 15%), net margin of -3,382.7% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is EXOZ's AI grade for 2026?
Our dual AI analysis gives Exozymes Inc.. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is EXOZ's free cash flow?
Exozymes Inc..'s operating cash flow is $-1.5M, with capital expenditures of $57.6K. FCF margin is -2,257.8%.
How does EXOZ compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -3,382.7% (avg: 12%), ROE -155.1% (avg: 15%), current ratio 1.32 (avg: 2).